levofloxacin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   137 Trials   137 Trials   5343 News 


«12...6465666768697071727374...9091»
  • ||||||||||  ciprofloxacin oral / Generic mfg.
    Journal:  Effect of Polymerization Time on the Binding Properties of Ciprofloxacin-Imprinted nanoMIPs Prepared by Solid-Phase Synthesis. (Pubmed Central) -  Aug 29, 2021   
    The results show that different polymerization times produce nanoMIPs with different binding properties: short polymerization times (15 min) produced nanoMIPs with high binding affinity but low selectivity (K > 10 mol L, α ≈ 1); medium polymerization times (30 min-2 h) produced nanoMIPs with high binding affinity and selectivity (K ≥ 10 mol L, α 2 h) produced nanoMIPs with low binding affinity, fast dissociation kinetics and low selectivity (K ≤ 10 mol L, k > 0.2 min, α ≈ 1). The results can be explained as the combined effect of rearrangement and progressive stiffening of the polymer chains around the template molecules.
  • ||||||||||  levofloxacin / Generic mfg.
    Journal:  Development of Chitosan/Cyclodextrin Nanospheres for Levofloxacin Ocular Delivery. (Pubmed Central) -  Aug 29, 2021   
    This surface property could promote the interaction of NPs with the negatively charged ocular tissue, increasing their residence time and, consequently, LVF efficacy. In vitro, antibacterial activity against Gram-positive and Gram-negative bacteria showed a double higher activity of CH/SBE-β-CD NPs loading LVF compared to the free drug, suggesting that chitosan NPs based on SBE-β-CD could be a useful system for the treatment of ocular infections.
  • ||||||||||  Retrospective data, Journal:  Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis-A Network Meta-Analysis. (Pubmed Central) -  Aug 28, 2021   
    Eighteen trials which reported on treatment with aztreonam lysine, tobramycin, colistin, levofloxacin, fosfomycin/tobramycin, and amikacin in various dosages were eligible for inclusion...Regarding change in CFQR-RSS, aztreonam lysine (t.i.d., 75 mg) and aztreonam lysine (b.i.d., 75 mg) with a 28-day run in the tobramycin inhalation solution phase had the highest probability of being the most effective treatments (SUCRA:74% and 72%, respectively)...According to CFQR-RSS no significant differences were found. Given the limitations of the studies included, validation trials are called for.
  • ||||||||||  rifampicin / Generic mfg.
    Journal:  Antimicrobial Resistance of Enterococcus sp. Isolated from Sheep and Goat Cheeses. (Pubmed Central) -  Aug 28, 2021   
    Continuous identification of Enterococcus sp. and monitoring of their incidence and emerging antibiotic resistance is important in order to prevent a potential risk to public health caused by the contamination of milk and other dairy products, such as cheeses, made on farm level.
  • ||||||||||  ciprofloxacin oral / Generic mfg., levofloxacin / Generic mfg.
    Clinical, Journal:  Influence of Probiotics on the Development of Clostridioides difficile Infection in Patients Receiving Fluoroquinolones. (Pubmed Central) -  Aug 28, 2021   
    Patients who received probiotics had statistically significantly fewer C. difficile diagnostic stool tests performed (4% vs. 16%, p = 0.005) and fewer additional infectious diagnostic testing performed (4% vs. 10%, p = 0.096), respectively. Further research is warranted to optimize and standardize probiotic prescribing in high-risk patients.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    COVID-19 MANAGEMENT IN PATIENTS AFTER HEART TRANSPLANTATION (Room H - White 1) -  Aug 28, 2021 - Abstract #ESOT2021ESOT_592;    
    Starting treatment from the 1 st day of the onset of the disease allows you to manage successfully this infectious process. In addition to standard management (antibacterial and antiviral therapy, mucoactive agents, anticoagulants), temporal reduction of immunosuppression is a key to manage COVID-19.
  • ||||||||||  levofloxacin / Generic mfg.
    Journal:  Adsorption behaviours and transfer simulation of levofloxacin in silty clay. (Pubmed Central) -  Aug 28, 2021   
    Acidity, cations and soil organic matter could affect the adsorption of LVFX, with adsorption variation ratio of 3.3%, 3.4% and 0.6%, respectively. In addition, numerical simulation with Hydrus-1D was utilized, and the results show that LVFX may infiltrate into underground water through silty clay after 28 days and completely penetrate in 100 days.
  • ||||||||||  levofloxacin / Generic mfg.
    Clinical, Journal:  Cluster randomized trial of an antibiotic time-out led by a team-based pharmacist. (Pubmed Central) -  Aug 27, 2021   
    Implementation of a pharmacist-led ATO was feasible and well accepted but did not change overall antibiotic use. An ATO may promote increased use of oral antibiotics, but more effective strategies for self-stewardship are needed.
  • ||||||||||  ibuprofen / Generic mfg.
    Clinical, Journal:  Clinical characteristics and outcome of drug-induced liver injury in the older patients: from the young-old to the oldest-old. (Pubmed Central) -  Aug 26, 2021   
    Older patients with DILI exhibited an increasingly predominant cholestatic phenotype across a range of culprit drugs other that amoxicillin-clavulanate, with increased non-liver related mortality and require a different approach to predict outcome. The oldest DILI patients exhibited a particular phenotype with more severe DILI episodes and need to be considered when stratifying older DILI populations.
  • ||||||||||  levofloxacin / Generic mfg.
    Journal:  TiO2 thin-walled nanofiber burst tube doped with Fe2O3 nanograss for efficient degradation of levofloxacin: Effect of precursor. (Pubmed Central) -  Aug 25, 2021   
    However, the composite prepared by adding 2% K3[Fe(C2O4)3]·3H2O has the best synergistic effect, showing the best photoresponse performance and catalytic efficiency, and achieving the degradation of 94% levofloxacin within 90 min. In this study, a simple and economical synthesis strategy was proposed, that is, TiO2/Fe2O3 heterostructure with special structure was prepared by introducing a small amount of acid or metallic acid salts into the precursor as a high-performance photocatalyst.
  • ||||||||||  levofloxacin / Generic mfg., clarithromycin / Generic mfg., amoxicillin / Generic mfg.
    New trial:  CRIHEP: Helicobacter Pylori Resistance (clinicaltrials.gov) -  Aug 24, 2021   
    P,  N=185, Completed, 
  • ||||||||||  levofloxacin / Generic mfg., clindamycin phosphate / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg.
    Enrollment open:  Susceptibility Testing of Biofilm to Guide Treatment of Periprosthetic Joint Infections (clinicaltrials.gov) -  Aug 23, 2021   
    P=N/A,  N=40, Recruiting, 
    This work will improve the knowledge about the mechanism underlying the effects of antibiotics on the larval development of house flies in the environment and provide guidance for improving the application of house fly bioconversion. Not yet recruiting --> Recruiting
  • ||||||||||  rifampicin / Generic mfg., amoxicillin / Generic mfg.
    Journal:  Assessment of Anaplasma phagocytophilum presence in early Lyme borreliosis manifested by erythema migrans skin lesions. (Pubmed Central) -  Aug 22, 2021   
    phagocytophilum may be present in early Lyme borreliosis characterized by erythema migrans and should always be considered as a differential diagnostic following a tick bite and considered in treatment schemes, as these differs (in early stage of Lyme borreliosis doxycycline, amoxicillin, cefuroxime axetil and azithromycin are recommended, while in anaplasmosis the most effective courses of treatment are doxycycline, rifampin and levofloxacin). Consequently, the role of A. phagocytophilum in erythema migrans should be further studied.
  • ||||||||||  levofloxacin / Generic mfg., oseltamivir / Generic mfg.
    Journal:  Feature selection based multivariate time series forecasting: An application to antibiotic resistance outbreaks prediction. (Pubmed Central) -  Aug 20, 2021   
    Finally, to the best of our knowledge, this is the first time that a feature selection based multivariate time series methodology is proposed for antibiotic resistance forecasting. Final results show that the best model according to the proposed multi-criteria decision making process provides a RMSE = (0.1349, 0.1304, 0.1325) and a MAE = (0.1003, 0.096, 0.0987) for 1, 2, and 3 steps-ahead predictions.
  • ||||||||||  clarithromycin / Generic mfg., amoxicillin / Generic mfg.
    [VIRTUAL] What to Do With Antibiotic Resistant H. Pylori Infection? () -  Aug 19, 2021 - Abstract #APDW2021APDW_560;    
    Vonoprazan-based dual or triple therapies are promising alternative...Bismuth-based quadruple therapy or Levofloxacin/bismuth-based quadruple therapy combining either amoxicillin or tetracycline are recommended for rescue therapy...Bismuth has a synergistic effect with anti biotics, and overcomes clarithromycin resistance. Susceptibility-guided therapy or genotype resistance-guided therapy is recommended after multiple failures.
  • ||||||||||  clarithromycin / Generic mfg.
    [VIRTUAL] H. Pylori Eradication Strategy – East vs. West () -  Aug 19, 2021 - Abstract #APDW2021APDW_559;    
    The keys to curing the infection are to treat it as an infectious disease and rely on what works locally instead of guideline that have no relevance to local conditions. All guidelines must be developed locally.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date, Head-to-Head:  ENVELOPE: Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections. (clinicaltrials.gov) -  Aug 18, 2021   
    P3,  N=1492, Recruiting, 
    Trial completion date: Apr 2021 --> Jun 2022 | Trial primary completion date: Apr 2021 --> Dec 2021 Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Jul 2021 --> Oct 2021
  • ||||||||||  Sirturo (bedaquiline) / J&J, Pharmstandard
    Review, Journal:  Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries. (Pubmed Central) -  Aug 18, 2021   
    The use of WHO-recommended bedaquiline-containing regimens in the treatment of MDR-/RR-TB patients with undetected resistance to fluoroquinolones runs a high risk of acquired bedaquiline resistance, especially in settings with a high prevalence of fluoroquinolone resistance. It is crucial to mitigate the risks of both primary and acquired resistance of rifampicin, fluoroquinolone and bedaquiline by rational design of regimens and effective management of TB patients.